HYDROXOCOBALAMIN INJECTION USP Rx Only

Hydroxocobalamin injection is a sterile solution of hydroxocobalamin for intramuscular administration.

Each mL contains: Hydroxocobalamin Acetate equivalent to 1000 mcg Hydroxocobalamin, Sodium Acetate Anhydrous 0.2 mg, Glacial Acetic Acid 0.442 mg, Sodium Chloride 8.2 mg, with Methylparaben 1.5 mg and Propylparaben 0.2 mg as preservatives, in Water for Injection q.s. Additional Glacial Acetic Acid and/or Sodium Acetate may have been used to adjust pH. pH range is 3.5 to 5.0.

Hydroxocobalamin appears as dark red orthorhombic needles or as an amorphous or crystalline red powder. It is very hygroscopic in the anhydrous form, and moderately soluble in water. It has a molecular weight of 1346.37. The vitamin B₁₂ coenzymes are very unstable in light. Hydroxocobalamin shares the cobalamin molecular structure with cyanocobalamin.

The chemical name is α-(5,6-dimethylbenzimidazoly) hydroxocobamide. The empirical formula is C₆₂H₈₉CoN₁₃O₁₅P and its structural formula is:

The cobalt content is 4.34%.

Vitamin B₁₂ is essential to growth, cell reproduction, hematopoiesis, nucleoprotein and myelin synthesis.

Fifty percent of the administered dose of hydroxocobalamin disappears from the injection site in 2.5 hours. Hydroxocobalamin is bound to plasma proteins and stored in the liver. It is excreted in the bile and undergoes some enterohepatic recycling. Within 72 hours after injection of 500 to 1000 mcg of hydroxocobalamin, 16 to 66 percent of the injected dose may appear in the urine. The major portion is excreted within the first 24 hours.

1. Pernicious anemia, both uncomplicated and accompanied by nervous system involvement.

2. Dietary deficiency of Vitamin B₁₂, occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B₁₂ deficiency is very rare).

3. Malabsorption of vitamin B₁₂, resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B₁₂ absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B₁₂ deficiency.

4. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B₁₂ deficiency.

   Structural lesions leading to vitamin B₁₂ deficiency include regional ileitis, ileal resections, malignancies, etc.

5. Competition for Vitamin B₁₂ by intestinal parasites or bacteria.

   The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B₁₂ and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B₁₂ or folate.

6. Inadequate utilization of vitamin B₁₂. This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia.

7. For the Schilling Test.

Hypersensitivity to any component of this medication.

Avoid the intravenous route.

Folic acid is not a substitute for vitamin B₁₂ although it may improve vitamin B₁₂ deficient megaloblastic anemia. Exclusive use of folic acid in treating vitamin B₁₂ deficient megaloblastic anemia could result in progressive and irreversible neurologic damage.

Blunted or impeded therapeutic response to vitamin B₁₂ may be due to such conditions as infection, uremia, drugs having bone marrow suppressant properties such as chloramphenicol, and concurrent iron or folic acid deficiency.

Mild transient diarrhea, itching, transitory exanthema, feeling of swelling of entire body, and anaphylaxis.

A few patients may experience pain after injection of hydroxocobalamin.

To report SUSPECTED ADVERSE EVENTS, contact Actavis at 1-800-272-5525 or FDA at 1-800-FDA-1088 or www.fda.gov for voluntary reporting of adverse reactions.

The intravenous LD₅₀ of hydroxocobalamin in mice is greater than 50 mL/kg.

Protect from light.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Hydroxocobalamin injection should be given only intramuscularly.

In patients with Addisonian Pernicious Anemia, parenteral therapy with vitamin B₁₂ is the recommended method of treatment and will be required for the remainder of the patient’s life. Oral therapy is not dependable. In other patients with vitamin B₁₂ deficiency, the duration of therapy and route of administration will depend upon the cause and whether or not it is reversible.

Confirmatory diagnostic studies should be performed prior to initiating therapy, if possible, and the patient should be followed with appropriate studies to demonstrate hematologic improvement (Hgb, hematocrit, RBC, reticulocyte count). A diagnostic trial utilizing physiologic doses of vitamin B₁₂ (1 mcg daily) and observing daily reticulocyte counts after establishing a baseline may also be performed. The observation of reticulocytosis which usually occurs between the third and tenth day of therapy confirms the diagnosis of vitamin B₁₂ deficiency.

In seriously ill patients it may be advisable to administer both vitamin B₁₂ and folic acid while awaiting the results of distinguishing laboratory studies. It is not necessary to withhold vitamin B₁₂ therapy until the precise cause of B₁₂ deficiency is established since absorption studies can be performed at any time.

Serum potassium should be closely observed the first 48 hours and potassium should be administered if necessary.

Product: 50090-3548

NDC: 50090-3548-0 30 mL in a VIAL, MULTI-DOSE / 1 in a CARTON

Manufactured by: Hikma Farmaceutica (Portugal) S.A. 2705-906 Terrugem SNT, PortugalStore at 20°-25°C (68°-77°F). [See USP controlled room temperature.] PROTECT FROM LIGHT.